One patient has experienced an adverse reaction when using Curaderm
BEC5. The patient experienced some scarring after using Curaderm BEC5
for several months.
On assessment it was established that:
1. The patient had applied Curaderm BEC5 on DRY SPOTS on the skin
even though a dermatologist confirmed that THE PATIENT HAD NO SKIN
CANCER
2. The patient was on corticosteroid therapy which consisted of
prednisone and cortisone.
Prednisone and cortisone therapy have many side effects, including
adverse effects on the skin. Some reported side effects of prednisone
and cortisone taken orally result in the following:
Thinning of the skin, a tendency to bruise easily and extensively with
slight trauma, development of large bruises, decreased muscle mass and
weakness, dry skin, unusual skin growths, immune and inflammatory
suppression, resulting in infections, and wounds take longer to heal.
These steroids break down protein and suppress inflammation, and
initial fibrous tissue is not laid down in the normal way.
Conclusions
* Curaderm BEC5 should be used to treat non melanoma skin cancers
such as: keratosis, keratoacanthoma, basal cell carcinoma and non
metastasised squamous cell carcinoma. Patients should seek medical
advice for their skin lesions before using Curaderm BEC5 and not apply
Curaderm BEC5 on dry spots on the skin.
* Patients on corticosteroid therapy such as prednisone and/or
cortisone should not use Curaderm BEC5.
Curaderm Global Ltd
